
Asynt Ltd
Eight Reactions. One Platform. Faster Discovery at Heriot-Watt
The Donnelly Research Group, Heriot-Watt University (Edinburgh, UK) published a compelling case study highlighting significant operational and scientific advantages when performing parallel inert chemistry using the DrySyn OCTO 8-position Reaction Station, a compact benchtop synthesis platform.
Parallel reaction screening lies at the heart of modern synthetic chemistry, allowing researchers to explore reaction conditions, catalysts and atmospheres simultaneously with high precision. Traditionally, achieving this level of control has required multiple hotplates, gas manifolds and bespoke glassware setups. By contrast, the DrySyn OCTO integrates key reaction parameters including stirring, heating, inert atmosphere control and reflux into a single, space-efficient platform designed to simplify complexity without sacrificing performance.
In its impartial evaluation, the Donnelly Group implemented the DrySyn OCTO to conduct multiple inert reactions in parallel under tightly controlled and repeatable conditions, delivering notable improvements in experimental workflow and screening throughput. The system enables eight concurrent reactions in standard 5–6 mL glass tubes with gas-tight closures, facilitating inert atmosphere chemistry without the operational challenges associated with traditional multi-station gas manifolds. Researchers reported improved ease of use, enhanced reproducibility and a more streamlined approach to condition screening, particularly valuable in exploratory synthesis and catalyst development.
Dr Liam Donnelly, leader of the Donnelly Group, explained:
“We are leveraging the DrySyn OCTO parallel synthesis reactor to screen catalysts and reaction conditions for polymer backbone modification, enabling the design of new degradable polymers. This medium-throughput approach allows us to run multiple reactions simultaneously under precisely controlled conditions, dramatically reducing the time and resources needed to identify optimal pathways.”
